Offered by: Nemours Children's
Locations: Delaware Valley, Jacksonville, Fla., Orlando and Pensacola, Fla.
A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients With Recurrent, Refractory, or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
To find out what effects low and high doses of lenalidomide have on children, adolescents, and young adults with recurrent/refractory/progressive JPA or OPG.
Children with juvenile pilocytic astrocytomas (JPA) or an optic pathway glioma (OPG).
Length of study is 24 months. Standard cancer care.
Trial Name: A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients With Recurrent, Refractory, or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
ACNS#: 1022
(800) 354-5690 Email UsLearn more about clinical trials and get answers to questions you might have.
Go to FAQs View All Clinical TrialsNemours has a number of service regions. Selecting your region will help us show you the right contact information and the most relevant content for you.